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In Drosophila, the Slit gene product, a secreted glycoprotein, acts as a midline repellent to guide axonal development during
embryogenesis. Three human Slit gene orthologues have been characterised and recently we reported frequent promoter region
hypermethylation and transcriptional silencing of SLIT2 in lung, breast, colorectal and glioma cell lines and primary tumours.
Furthermore, re-expression of SLIT2 inhibited the growth of cancer cell lines so that SLIT2 appears to function as a novel tumour
suppressor gene (TSG). We analysed the expression of SLIT3 (5q35–34) and SLIT1 (1q23.3–q24) genes in 20 normal human tissues.
Similar to SLIT2 expression profile, SLIT3 is expressed strongly in many tissues, while SLIT1 expression is neuronal specific. We
analysed the 50 CpG island of SLIT3 and SLIT1 genes in tumour cell lines and primary tumours for hypermethylation. SLIT3 was found
to be methylated in 12 out of 29 (41%) of breast, one out of 15 (6.7%) lung, two out of six (33%) colorectal and in two out of (29%)
glioma tumour cell lines. In tumour cell lines, silenced SLIT3 associated with hypermethylation and was re-expressed after treatment
with 5-aza-20-deoxycytidine. In primary tumours, SLIT3 was methylated in 16% of primary breast tumours, 35% of gliomas and 38% of
colorectal tumours. Direct sequencing of bisulphite-modified DNA from methylated tumour cell lines and primary tumours
demonstrated that majority of the CpG sites analysed were heavily methylated. Thus, both SLIT2 and SLIT3 are frequently methylated
in gliomas and colorectal cancers, but the frequency of SLIT3 methylation in lung and breast cancer is significantly less than that for
SLIT2. We also demonstrated SLIT1 promoter region hypermethylation in glioma tumour lines (five out of six; 83%), the methylation
frequency in glioma tumours was much lower (two out of 20; 10%). Hence, evidence is accumulating for the involvement of
members of the guidance cues molecules and their receptors in tumour development.
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Epigenetic inactivation of tumour suppressor genes (TSGs) by
promoter region CpG island hypermethylation is now well
documented and several TSGs have been demonstrated to be
inactivated by this mechanism (reviewed in Jones and Baylin, 2002;
Herman and Baylin, 2003). In more recent years, a novel class of
TSGs has been identified where epigenetic inactivation plays the
predominant role, while somatic mutations are rare. This class of
genes is exemplified by the 3p21.3 TSG, Ras association domain
family 1A gene (RASSF1A) (Dammann et al, 2000; Lerman and
Minna, 2000; Agathanggelou et al, 2001; Burbee et al, 2001). The
CpG island in the promoter region of isoform A is frequently and
heavily methylated in many types of cancers, including lung,
breast, kidney, NPC, gastric, bladder, neuroblastoma, testicular,
etc. (reviewed in Pfeifer et al, 2002; Dammann et al, 2003), while
somatic inactivating mutations are absent or rare.
SLITs, ROBOs and Semaphorins belong to families of proteins
that play important roles in axon guidance and cell migration in
Drosophila and vertebrates (reviewed in Brose and Tessier-
Lavigne, 2000; Wong et al, 2002). These proteins are widely
expressed in mammalian tissues and the expression is not confined
to neurons. Hence, they may have other yet unidentified roles. Slits
are secreted proteins that are ligands for the Robo receptors (Brose
et al, 1999; Kidd et al, 1999; Li et al, 1999). Recently, Slit was shown
to inhibit leucocyte chemotaxis, this inhibition appears to be
mediated by Robo (Wu et al, 2001). In mammals, four Robo genes
have so far been identified, Robo1, Robo2, Rig-1 (Robo3) and magic
Robo (Robo4) (Kidd et al, 1998; Sundaresan et al, 1998; Yuan et al,
1999; Huminiecki et al, 2002). In humans, ROBO1 is located at
3p12 within a critical region of overlapping homozygous deletions
in lung and breast cancers (Sundaresan et al, 1998). This region
also demonstrated a high frequency of allele loss in lung, kidney
and breast cancers. Majority of mice with deletion of exon 2 of
Robo1 die at birth because of delayed lung maturation, the
surviving mice develop bronchial hyperplasia (Xian et al, 2001). In
an earlier study, we demonstrated that there were no inactivating
somatic mutations in ROBO1 in lung and breast cancers, but a CpG
island in the 50 region of ROBO1 was hypermethylated in breast
and kidney tumours (Dallol et al, 2002b). We went on to analyse
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sthe ligand SLIT2 located at 4p15.2 for genetic/epigenetic inactiva-
tion in tumours. The 4p15.2 region shows frequent allele loss in
lung, breast, colorectal and head and neck cancers. SLIT2
promoter region CpG island was found to be frequently
hypermethylated in lung, breast, colorectal and glioma tumours,
while somatic mutations were not found (Dallol et al, 2002a,
2003a,b). Furthermore, we demonstrated in vitro growth suppres-
sion when SLIT2 was expressed in tumour cell lines that had no
endogenous SLIT2 expression due to methylation. A recent paper
demonstrated that in mice slit2 homozygous deficiency was lethal
(Plump et al, 2002).
In this report, we analysed the methylation status of 50 CpGs
islands for the remaining SLIT gene family members (SLIT3 and
SLIT1) in human cancers.
MATERIALS AND METHODS
Patients and samples
A total of 60 glioma samples, plus seven glioma tumour cell lines
(T17, U87-MG, A172, U343, HS683, U373, H4) were analysed for
methylation. Among the glioma samples, 40 were classified as
gliomblastoma multiforme. The remaining gliomas were collected
randomly and consisted of all grades. In addition, 32 colorectal
cancer samples and their matching histologically normal mucosa,
six colorectal tumour cell lines (SW48, HCT116, LS411, LS174T,
DLD1, LoVo), 15 lung tumor cell lines, 32 invasive ductal breast
carcinoma plus 29 breast tumour cell lines were also analysed for
methylation. These have been described previously (Dallol et al,
2002a, 2003a,b)
Bisulphite modification and methylation analysis
Bisulphite DNA sequencing was performed as described pre-
viously (Agathanggelou et al, 2001). Briefly, 0.5–1.0mgo f
genomic DNA was denatured in 0.3 M NaOH for 15min at
371C. Unmethylated cytosine residues were then sulphonated by
incubation in 3.12 M sodium bisulphite (pH 5.0) (Sigma, Dorset,
UK) and 5mM hydroquinone (Sigma) in a thermocycler
(Hybaid) for 15s at 991C and 15min at 501C for 20 cycles.
Sulphonated DNA was then recovered using the Wizard DNA
cleanup system (Promega, Southampton, UK) according to the
manufacturers’ instructions. The DNA was desulphonated by
addition of 0.3 M NaOH for 10min at room temperature. The
converted DNA was then ethanol precipitated and resuspended
in water.
Table 1 Expression and methylation primer sequences and PCR conditions
Primer name Primer sequence (50 to 30)
Annealing temp. for
PCR (1C)
MgCl2 conc.
(mM)
Predicted product
size (bp)
SLIT3 COBRA F GGT-TAG-TTT-ATT-YGG-TYG-TTT-YGT-G TT-TTA-GT 55 1.5 394
SLIT3 COBRA R TAC-CCA-CCC-RAA-AAC-CAT-AAT-ATA-CAA-AA
SLIT3 COBRA RN CCA-CTC-CTA-AAA-AAA-ACT-ACC-TCT-A
SLIT1 COBRA F GTT-TAT-TTT-TTT-TTT-YGT-AGT-AGT-TAG-TTG-GGA-GT 57 1.5 370
SLIT1 COBRA R TAA-CAA-TCC-ACC-RTA-ATT-CCR-ATA-CAA-ATA-CAA-AAA
SLIT1 COBRA FN GGY-GAA-AYG-GTA-GAG-GAG-TYG-AGT-TTT-T
GAPDH expression F TGA-AGT-TCG-GAG-TCA-ACG-GAT-TTG-GT 60 1.5 982
GAPDH expression R CAT-GTG-GGC-CAT-GAG-GTC-CAC-CAC
SLST3 expression F CAA-GTG-TGC-CGA-GGG-CTA-TGG-AG 65 1.5 419
SLIT3 expression R ACG-GG C-TTA-GGA-ACA-CGC-GAG-G
SLIT1 expression F GTG-ACA-ACT-GCA-GTG-AGA-AC 55 1.5 422
SLIT 1 expression R GTA-CAG-CTC-AAC-TGC-AAT-GT
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Figure 1 Quantitative real-time RT–PCR was used to measure SLIT1 and 3 expression levels in 20 normal human tissues. See Materials and Methods for
real-time RT–PCR details. RPLPO gene transcript was used as the endogenous RNA control and each sample was normalised on the basis of its RPLPO
content.
Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers
RE Dickinson et al
2072
British Journal of Cancer (2004) 91(12), 2071–2078 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sCombined bisulphite restriction analysis (COBRA) and
sequencing
All reactions were performed on a thermocylcer (Hybaid) and with
HotStar Taq Polymerase (Quiagen, West Sussex, UK). The
promoter methylation status of SLIT3 and SLIT1 were determined
using the COBRA method followed by sequencing to confirm
methylation and ascertain the extent of methylation. The cycling
conditions were as follows: initial denaturation for 10min at 951C,
followed by 25–35 cycles of 1min at 951C, 1min at annealing
temperature and 2min at 741C with a final extension for 5min at
741C using the forward and reverse primers. The reaction volume
of 20ml contained 40ng bisulphate-modified DNA, 1  PCR Buffer
containing 1.5mM MgCl2 (Quiagen), 0.2 M dNTPs, 0.4mM each
primer and 0.5U HotStar Taq (Qiagen). Then, 1ml of this reaction
was used in a seminested PCR reaction (50ml) using forward and
reverse nested primers in the case of SLIT3 and reverse and
forward nested primers for SLIT1. The same PCR programme and
concentration of reagents were used as before. The annealing
temperature, MgCl2 concentration and sequences for the gene
primers are listed in Table 1 (Y¼C or T and R¼A or G). All PCR
products were assayed for methylation by incubation with BstUI at
601Co rTaq
aIa t6 5 1C for 2h before visualisation on a 2% agarose
gel with added ethidium bromide. The CpG island methylation
status for SLIT3 was determined by cloning PCR products into
pGEM T-Easy vector (Promega – according to manufacturers’
instructions). At least five clones from each PCR product were then
prepared for sequencing. SLIT3 Colony PCR products were
purified using the QIAquick PCR Purification Columns (Quiagen
– according to manufacturers’ instructions) and then reamplified
using ABI BigDye Cycle Sequencing Kit (Perkin-Elmer, Warring-
ton, UK) with the reverse nested primer (as shown in Figure 2A).
The SLIT1 COBRA PCR products were purified and then
40 41     42  43   44 45   46    47      48  
cg
acccctacccacccgaaaaccataatatacaaaaccccgctcctaaaaaaaactacctctacgaaacaaaacgcgtaaaacccgaaaaaacgc
gcgaaaaacgcgaacgacctaaaaaacgaacga aaattaacgcgaaaaaaaaacgaactcgatactcaaacgcacgaaacgcgaacgaaac
gaaacgctccgaacgacgacgacgacaacaacaacaactccatcgacgaaaccgacgctaccccgctacgcatcgctaaaaatacccaaatac
gaaacgccccctaaccccgctaacccgcgaaccgaattaaaaacctaaaacgaacgcaataaaacgtaacgcccgaaaaaatccgacttaaaa
ctaaactaaaaaacgcgacgactacgactaaaacacgaaacgaccgaataaact
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Figure 2 (A) Sequence of the reverse bisulphate-modified SLIT3 promoter region CpG island fragment. Arrows indicate the position of the primers for
COBRA. CG dinucleotides within the amplification region are numbered 1–52 and sequences underlined are BstUI and TaqI sites used to detect
methylation. The expected amplicon size from SLIT3 COBRA F to SLIT3 COBRA RNested is 394bp. The box represents the transcriptional start site of
SLIT3.( B) Sequence of the reverse bisulphate-modified SLIT1 promoter region CpG island fragment. Arrows indicate the position of the primers for
COBRA. CG dinucleotides within the amplification region are numbered 1–39 and sequences underlined are BstUI sites used to detect methylation. The
expected amplicon size for SLIT1 FNested to SLIT1 R is 370bp. The box represents the transcriptional start site of SLIT1.
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The reactions were then analysed using an ABI Prism 377 DNA
sequencer (Perkin–Elmer).
Real-time RT–PCR
The theoretical and practical aspects of real-time quantitative RT–
PCR using the ABI Prism 7700 Sequence Detection System
(Perkin–Elmer) have been described in detail elsewhere (Dallol
et al, 2002a). Briefly, total RNA was reverse transcribed before real-
time PCR amplification. Quantitative values were obtained from
the threshold cycle (Ct) number at which the increase in the signal
associated with exponential growth of PCR products begins to be
detected using the PE Biosystems analysis software, according to
the manufacturers’ manuals. The precise amount of total RNA
added to each reaction mix and the quality was difficult to assess.
We therefore also quantified transcripts of the gene RPLPO (also
known as 36B4) encoding human acidic ribosomal phosphoprotein
PO as the endogenous RNA control, and each sample was
normalised on the basis of its RPLPO content. Results, expressed
as N-fold differences in target gene expression relative to the
RPLPO gene, termed ‘Ntarget’, were determined by the formula:
Ntarget¼2
DCtsample, where DCt value of the sample was determined
by subtracting the Ct value of the target gene from the Ct value of
the RPLPO gene. The nucleotide sequences of the primers used for
PCR amplification were the following: SLIT1-U (50-CTGGATGG
CTTGAGGACCCTAAT-30) and SLIT1-L (50-GCCCGTGAAGCTGTC
GTTGT-30) with a SLIT1-specific product size of 72bp, SLIT3-U
(50-GAATATGTCACCGACCTGCGACT-30) and SLIT3-L (50-GCAG
GTTGGGCAACTTCTTGA-30) with a SLIT3-specific product size of
85bp, and RPLPO-U (50-GGCGACCTGGAAGTCCAACT-30) and
RPLPO-L (50-CCATCAGCACCACAGCCTTC-30) with a RPLPO-
specific product size of 149bp. PCR was performed using the
SYBR
s Green PCR Core Reagents kit (Perkin–Elmer). To avoid
amplification of contaminated genomic DNA, one of the two
primers was placed at the junction between two exons. The thermal
cycling conditions comprised of an initial denaturation step at
951C for 10min and 50 cycles of 951C for 15s and 651C for 1min.
Cell lines and 5-aza-20 deoxycytidine treatment
Breast, colorectal and glioma tumour cell lines were routinely
maintained in RPMI 1640 (Invitrogen, San Diego, CA, USA)
supplemented with 10% FCS at 371C, 5% CO2.5 – 1 0  10
5 cells
were plated and allowed 24h growth before addition of 5-aza-20-
deoxycytidine (Sigma). The medium was changed 24h after
treatment and then every 3 days. RNA was prepared at 5 and 7
days after treatment using the Rneasy kit (Qiagen) according to
manufacturers’ instructions.
Expression analysis
Breast, colorectal and glioma cell line were treated with 5mM
demethylating agent 5-aza-20-deoxycytidine freshly prepared in
ddH2O and filter-sterilised. Extracted RNA (1mg) was used as a
template for cDNA synthesis using SuperScriptt III RNase H
 
Reverse Transcriptase (Invitrogen – according to the manufac-
turers’ instructions). In total, 2ml (10%) of the first strand reaction
was used for PCR (Invitrogen – according to the manufacturers’
instructions). Primers used for SLIT1, SLIT3 and GAPDH RT–PCR
are described in Table 1. The PCR theromocycle (Hybaid)
consisted of an initial denaturation of 10min at 951C followed
by 35 cycles of 951C for 30s, annealing temperature for 30s, 721C
for 30s and a final extension of 5min at 721C. PCR products were
visualised on a 2% agarose gel with added ethidium bromide.
RESULTS
SLIT1 and SLIT3 expression analysis in normal tissues
using quantitative real-time RT–PCR
We investigated the expression pattern of SLIT1 and SLIT3 genes
in a wide range of normal human tissues using quantitative real-
time RT–PCR (see Materials and Methods). SLIT3 was expressed
in majority of tissues analysed, with the highest expression in skin,
brain cerebellum and lung and lowest expression in fetal liver,
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Figure 3 (A) SLIT3 CpG island COBRA PCR products were cloned and sequenced from breast (MCF7, HCC712, HCC38 and HCC70) and colorectal
(SW48) tumour cell lines. For each tumour cell line, several clones were sequenced and the methylation status for the first 30 CpGs is shown. White and
black squares represent unmethylated and methylated CpGs, respectively. Partially filled squares represent partially methylated CpGs. (B) Expression of
SLIT3 in methylated breast (MCF7) and colorectal (SW48) cell lines before and after treatment with the demethylating agent 5-aza-20-deoxycytidine (5-aza
dC). Gene expression was restored by 5-aza-dC (þ) in methylated cell lines that lacked SLIT3 expression. GAPDH and the unmethylated glioma cell line
T17 were used as positive controls to ensure RNA integrity and equal loading.
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more restricted (brain and nervous system) (Figure 1).
Epigenetic inactivation of the SLIT3 gene in tumour cell
lines
The SLIT3 putative promoter region was predicted by Promoter
Inspector software (http://www.genomatrix.de). This region is
from  576 to þ9 relative to the translation start site. This region
fulfilled the criteria of a CpG island with a GC content of 77%
and an observed:expected CpG ratio of 0.86 (CpG plot
programme at http://www.ebi.ac.uk/Tools/). We investigated the
methylation status of this 50 CpG island associated with the SLIT3
gene in various human tumour cell lines. For this analysis, we
utilised the COBRA assay on bisulphite-modified DNA. Figure 2A
shows the sequence of the region analysed and the primers used
(sequence shown is reverse strand bisulphite modified and all CG
methylated), TaqI and BstUI sites are underlined. This CpG
island was found to be hypermethylated in 12 out of 29 (41%)
breast, one out of three (33%) NSCLC, zero out of 12 (0%) SCLC,
two out of six (33.3) colorectal and in two out of seven (29%)
glioma tumour cell lines. The COBRA PCR products were cloned
and several clones of each tumour cell line were sequenced to
determine the pattern and extent of methylation. As seen in
Figure 3A, majority of the 30 CG dinucleotides were hyper-
methylated for MCF-7, HCC712 and HCC38 (breast tumour lines)
and SW48 (colorectal tumour line), while breast tumour cell line
HCC70 was unmethylated. SLIT3 expression was restored in
tumour lines that were heavily methylated (MCF-7 and SW48) by
treating the cell lines with 5aza-2-deocycytidine (Figure 3B),
while the unmethylated glioma tumour cell line T17 did not show
any change in expression.
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Figure 4 (A) Relative expression of SLIT3 gene in methylated (M) and unmethylated (U) breast tumours using real-time RT–PCR as described in
Materials and Methods (B) BstUI digest of SLIT3 CpG island COBRA PCR products from glioma (T208, T116, T45) and colorectal (T46, T49) primary
tumours. (C) COBRA PCR products from glioma and colorectal primary tumours were cloned and sequenced. For each tumour, several clones were
sequenced and the methylation status for the first 30 CpGs is shown. White and black squares represent unmethylated and methylated CpGs, resepectively.
Partially filled squares represent partially methylated CpGs. 7T and 3T represent colorectal tumours, 7N and 3N represent corresponding normal colon
samples. 209T and 205T represent glioma tumours.
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sEpigenetic inactivation of the SLIT3 gene in primary
tumours
We then analysed the methylation status of the above CpG island
in primary tumours using COBRA analysis followed by sequencing
of the cloned PCR products. Five out of 32 (16%) breast tumours
were found to be methylated for SLIT3. Using real-time RT–PCR,
we demonstrated that the SLIT3 methylation in breast tumours
correlated with reduced SLIT3 expression as compared to
unmethylated breast tumours (Figure 4A). SLIT3 50 CpG island
was also hypermethylated in 12 out of 32 (37.5%) colorectal
tumours and in 21 out of 60 (35%) glioma primary tumours. Since
the tumour samples used in this study were not microdissected, in
majority of the primary tumors unmethylated bands were also
detected. No methylation was found in corresponding normal
tissues from the colorectal or glioma patients or in the DNA
isolated from normal brains. Similar to the tumour cell line data,
sequencing of cloned PCR products confirmed that majority of the
30 CG dinculeotides analysed were methylated in primary tumours
(Figure 4B, C).
Epigenetic inactivation of SLIT1 gene in gliomas
The SLIT1 CpG island was predicted to be from  574 to þ192 and
had a GC content of 71% and had an observed:expected CpG ratio
of 0.81 (CpG plot programme at http://www.ebi.ac.uk/Tools/). This
region overlapped with the SLIT1 putative promoter region
predicted by Promoter Inspector software (http://www.genoma-
trix.de). Since SLIT1 expression is neuronal specific, we analysed
the methylation status of the 50 CpG island of the SLIT1 gene in
glioma tumour cell lines and primary tumours by COBRA and
direct sequencing of bisulphite-modified DNA (Figure 2B). Five
out of six (83%) glioma tumour lines were methylated, while only
two of 20 (10%) glioma tumours demonstrated SLIT1 methylation
(Figure 5A, B). No methylation was found in DNA isolated from
normal brains. SLIT1 expression was restored/upregulated in five
glioma tumour lines (methylated for SLIT1) by treatment with 5-
aza-20-deoxycytidine (Figure 5C).
DISCUSSION
The Slit genes encode ligands for the roundabout (robo) receptors.
The Slit–Robo interactions mediate the repulsive cues on axons
and growth cones during neural development. The Slit family
comprises of large extracellular matrix-secreted and membrane-
associated glycoproteins with multiple functional domains (re-
viewed in Brose and Tessier-Lavigne, 2000). Slit genes have been
identified in Drosophila, Caenorhabditis elegans, Xenopus, chick-
ens, mice, rats and humans. There are three known mammalian
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Figure 5 (A) BstUI digest of SLIT1 COBRA PCR products from glioma grade IV tumours and normal brain (N6 and N3) which were included as negative
controls for methylation. Tumours 19 and 73 show digestion with BstUI. (B) SLIT1 COBRA PCR products were directly sequenced from glioma tumour cell
lines and normal brain. The methylation status from CpG 19–37 is shown. White and black squares represent unmethylated and methylated CpGs,
respectively. Partially filled squares represent partially methylated CpGs. Glioma tumour cell line Hs683 is unmethylated for SLIT1 (C) Expression of SLIT1 in
glioma tumour cell lines before and after treatment with 5-aza-20-deoxycytidine. GAPDH was used as positive control to ensure RNA integrity and equal
loading.
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10q23.3–q24, 4p15.2 and 5q35–q34, respectively. slit2 and slit3
genes are expressed in neuronal as well as nonneuronal tissues,
while slit1 expression is specific to the brain (Wu et al, 2001 and
this report). Slit2 homozygous deficiency in mice is lethal, while
Slit1 and Slit3 homozygous mice are viable (Plump et al, 2002;
Yuan et al., 2003).
In our earlier studies, we demonstrated that the ligand (SLIT2)
for robo1 receptor was frequently methylated in lung, breast,
colorectal and glioma tumours and that the methylation
correlated with loss of SLIT2 expression. More recently, we
demonstrated SLIT2 methylation in neuroblastoma, Wilms’
tumour and renal cell carcinoma (Astuti et al, 2004). Further-
more, in in vitro assays, SLIT2 suppressed tumour growth (Dallol
et al, 2002a, 2003a,b).
SLIT3 is located at 5q35-q34, which is a frequent region of allelic
loss in colorectal and lung cancers (Girard et al, 2000; Goel et al,
2003). We have now demonstrated that SLIT3 50 CpG island similar
to SLIT2 is frequently hypermethylated in colorectal and glioma
tumours and less so in breast tumours. And loss of SLIT3
expression can be reversed by treatment with a demethylating
agent. While SLIT1 gene is frequently methylated in glioma
tumour lines but at low frequencies in glioma tumours, hence
SLIT1 may play a role in late gliomagenesis.
Slits, netrins, semaphorins and the ephrins constitute conserved
families of axonal guidance cues that have prominent develop-
mental effects. Recently, SEMA3B was also demonstrated to be
inactivated in lung cancer by promoter region hypermethylation
(Tomizawa et al, 2001; Kuroki et al, 2003). Re-expression of
SEMA3B inhibited lung cancer cell growth and induced apoptosis.
The finding of epigenetic inactivation in various human cancers
of ROBO1, SEMA3B, SLIT2 and now SLIT3 and to a lesser extent
SLIT1, all of which are involved in axon and cell migration in
Drosophila and vertebrates, suggests a novel, and common
underlying theme for these molecules in tumour suppression.
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